Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Cancer. 2017 May 30;123(19):3791–3798. doi: 10.1002/cncr.30791

Figure 2.

Figure 2

Figure 2

Figure 2

Cumulative incidence of (a) ED/TRM as first event for all patients on AML97 and AML02, (b) TRM as first event for patient in receiving chemotherapy or autologous HCT and (c) TRM as first event for patients receiving allogeneic HCT.